1092563-68-2

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(1-Boc-4-piperidyl)-3-methylpyrazole-4-boronic Acid Pinacol Ester serves as a crucial building block in the synthesis of pharmaceuticals and other biologically active compounds. Its ability to form carbon-carbon bonds and its potential for binding to biological targets make it a valuable component in creating new drugs and therapeutic agents.
Used in Organic Synthesis:
In the realm of organic synthesis, 1-(1-Boc-4-piperidyl)-3-methylpyrazole-4-boronic Acid Pinacol Ester is utilized as a versatile intermediate. Its capacity to participate in various reactions, including but not limited to Suzuki-Miyaura cross-coupling, allows for the creation of complex organic molecules that are essential in a wide array of chemical applications.
Used in Medicinal Chemistry:
1-(1-Boc-4-piperidyl)-3-methylpyrazole-4-boronic Acid Pinacol Ester is also employed in medicinal chemistry for the development of new pharmaceutical entities. Its unique structure and functional groups enable it to be a key component in the design and synthesis of molecules with specific biological activities, contributing to advancements in drug discovery and development.

Upstream product

• 1076223-99-8 tert-butyl 4-(4-bromo-5-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1092500-89-4 tert-butyl 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR

Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.

PYRIDINE AND PYRAZINE DERIVATIVES - 083

The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS

The invention concerns pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of G1, G2, Ring A, R1, m, R2, R3, n and R4 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositionscontaining them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES

The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases